Role of Multifunctional Cell Cycle Modulators in Advanced Secondary Hyperparathyroidism

Therapeutic Apheresis and Dialysis

Volumn 15, Issue SUPPL.1, 2011, Pages 26-32

  Sato, Tetsuhiko ^a   Kikkawa, Yamato ^b   Hiramitsu, Takahisa ^a   Yamamoto, Takayuki ^a   Goto, Norihiko ^a   Matsuoka, Susumu ^a   Nagasaka, Takaharu ^a   Watarai, Yoshihiko ^a   Uchida, Kazuharu ^a   Tominaga, Yoshihiro ^a  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

CCAAT enhancer binding protein (C EBP) ; Ras; Secondary hyperparathyroidism

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CYCLIN D1; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN;

ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DIALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; PARATHYROID CELL; PARATHYROID HYPERPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SECONDARY HYPERPARATHYROIDISM; UREMIA;

CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL PROLIFERATION; CYCLIN D1; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPLASIA; KI-67 ANTIGEN; MITOGEN-ACTIVATED PROTEIN KINASES; PARATHYROID GLANDS; PHOSPHORYLATION; RAS PROTEINS; STAINING AND LABELING; UP-REGULATION;

EID: 79956209476     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00922.x     Document Type: Article

References (24)

1. Kestenbaum B, Seliger SL, Gillen DL etal. Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney Int 2004;65:282-8.
2. Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997;13:78-86.
3. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-43.
4. Gogusev J, Duchambon P, Hory B etal. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51:328-36.
5. Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 2002;62:1196-207.
6. Mizobuchi M, Hatamura I, Ogata H etal. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004;15:2579-87.
7. Fukagawa M, Tominaga Y, Kitaoka M, Kakuta T, Kurokawa K. Medical and surgical aspects of parathyroidectomy. Kidney Int Suppl 1999;73:S65-69.
8. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 2002;365:561-75.
9. Descombes P, Schibler UA. Liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 1991;67:569-79.
10. Sundfeldt K, Ivarsson K, Carlsson M etal. The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. Br J Cancer 1999;79:1240-8.
11. Rask K, Thorn M, Ponten F etal. Increased expression of the transcription factors CCAAT-enhancer binding protein-beta (C/EBBeta) and C/EBzeta (CHOP) correlate with invasiveness of human colorectal cancer. Int J Cancer 2000;86:337-3343.
12. Li W, Kessler P, Yeger H etal. A gene expression signature for relapse of primary Wilms tumors. Cancer Res 2005;65:2592-601.
13. Nakajima T, Kinoshita S, Sasagawa T etal. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci USA 1993;90:2207-11.
14. Kowenz-Leutz E, Twamley G, Ansieau S, Leutz A. Novel mechanism of C/EBP beta (NF-M) transcriptional control: activation through derepression. Genes Dev 1994;8:2781-91.
15. Lamb J, Ramaswamy S, Ford HL etal. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003;114:323-34.
16. Tang Q-Q, Otto TC, Lane MD. CCAAT/enhancer-binding protein beta is required for mitotic clonal expansion during adipogenesis. Proc Natl Acad Sci USA 2003;100:850-5.
17. Zhang JW, Tang Q-Q, Vinson C, Lane MD. Dominant-negative C/EBPβ disrupts mitotic clonal expansion and differentiation of 3T3-L1 preadipocytes. Proc Natl Acad Sci USA 2004;101:43-7.
18. Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC. CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proc Natl Acad Sci USA 2002;99:207-12.
19. Grimm SL, Contreras A, Barcellos-Hoff MH, Rosen JM. Cell cycle defects contribute to a block hormone-induced mammary gland proliferation in CCAAT/enhancer-binding protein (C/EBP)β-null mice. J Biol Chem 2005;280:36301-9.
20. Zahnow CA, Cardiff RD, Laucirica R, Medina D, Rosen JM. A role for CCAAT/enhancer binding protein beta-liver-enriched inhibitory protein in mammary epithelial cell proliferation. Cancer Res 2001;61:261-9.
21. Dusso AS, Sato T, Arcidiacono MV etal. Pathogenic mechanisms for parathyroid hyperplasia. Kidney Int 2006;70:S8-S11.
22. Baldwin BR, Timchenko NA, Zahnow CA. Epidermal growth factor receptor stimulation activates the RNA binding protein CUG-BP1 and increases expression of C/EBPβ-LIP in mammary epithelial cells. Mol Cell Biol 2004;24:3682-91.
23. Cozzolino M, Lu Y, Sato T etal. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol 2005;289:F1096-1102.
24. Hirai T, Nakashima A, Takasugi N, Yorioka N. Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial 2010;14:577-82.